Nemaura Medical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch NMRD and buy or sell other stocks, ETFs, and their options commission-free!

About NMRD

Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. Through its subsidiaries, it manufactures and commercializes continuous glucose monitoring system, named sugarBEAT. 

CEO
Dewan Fazlul Hoque Chowdhury
CEODewan Fazlul Hoque Chowdhury
Employees
8
Employees8
Headquarters
Loughborough, Leicestershire
HeadquartersLoughborough, Leicestershire
Founded
2013
Founded2013
Employees
8
Employees8

NMRD Key Statistics

Market cap
2.09B
Market cap2.09B
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
42.79K
Average volume42.79K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$2.00
52 Week high$2.00
52 Week low
$0.383
52 Week low$0.383

Stock Snapshot

The current Nemaura Medical(NMRD) stock price is $10.06, with a market capitalization of 2.09B. It offers a dividend yield of 0.0%.

Nemaura Medical(NMRD) stock opened on 2026-03-25 at —. The price climbed to — and dipped to —.

Nemaura Medical(NMRD) shares are trading with a volume of 0, against a daily average of 42.79K.

In the last year, Nemaura Medical(NMRD) shares hit a 52-week high of $2.00 and a 52-week low of $0.38.

In the last year, Nemaura Medical(NMRD) shares hit a 52-week high of $2.00 and a 52-week low of $0.38.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.